Humacyte, Inc. announced the appointment of Jim Mercadante as Chief Commercial Officer. Mercadante, a veteran commercial executive with more than 25 years of experience in the healthcare and medical technology industries, will oversee all aspects of the Company's commercial strategy, including sales, marketing, and market access, as Humacyte continues to expand the U.S. launch of Symvess and prepares for potential future commercial indications. Mr. Mercadante is a seasoned commercial executive with a track record of successful leadership across medical devices, diagnostics, and healthcare technology.
Over his career, he and his teams have launched over 50 new products and delivered millions of dollars in growth for multiple companies. Mercadante has held senior leadership positions at prominent healthcare companies, including Abbott, Johnson & Johnson, GE, Terumo, and Rapid AI, overseeing and building deep expertise in sales marketing, commercial operations, strategic partnerships and national accounts which delivered rapid and significant sales growth across both U.S. and international markets. He most recently served as Chief Commercial Officer of Qure.ai, a global provider of AI-powered healthcare solutions, where he led global sales and business development strategy.
Symvess is the Company's first FDA-approved product, indicated for the treatment of extremity vascular trauma. Since its commercial launch, Humacyte has continued to expand access to Symvess through hospital Value Analysis Committee (VAC) approvals, inclusion in the U.S. Defense Logistics Agency's Electronic Catalog (ECAT), and international regulatory expansion, including a Marketing Authorization Application filing in Israel.
